Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds.
Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds. The company's technologies provide integrated control solutions, including the use of technical expertise to optimize the process and increase protein expression to reduce production scale, providing bio-pharmaceutical companies with personalized, chemical-defined cell culture media, formula production, technical support and ancillary services.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 10, 2021 | Series C | ¥400M | 1 | — | — | Detail |
Jul 24, 2020 | Series B | — | 1 | — | — | Detail |
Jun 1, 2020 | Series Unknown | — | 1 | — | — | Detail |
Jan 1, 2019 | Series A | ¥300M | 2 | — | — | Detail |
Jan 2, 2017 | Angel | — | 1 | Blue Bay Science Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Jinshi Investment | — | Series C |
Huaxu Investment | — | Series B |
Yinglian Health Fund | — | Series Unknown |
Blue Bay Science Capital | — | Series A |
TenYall & Sumin | — | Series A |